In the BioHarmony Drug Report Database

"Preview" Icon

Cangrelor

Kengreal, Kengrexal (cangrelor) is a small molecule pharmaceutical. Cangrelor was first approved as Kengreal on 2015-03-23. It has been approved in Europe to treat acute coronary syndrome and vascular surgical procedures. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and P2Y purinoceptor 13. Kengreal’s patents are valid until 2035-07-10 (FDA).

 

Trade Name

 

Kengrexal
 

Common Name

 

cangrelor
 

ChEMBL ID

 

CHEMBL334966
 

Indication

 

acute coronary syndrome, vascular surgical procedures
 

Drug Class

 

Platelet aggregation inhibitors

Image (chem structure or protein)

Cangrelor structure rendering